The Nanosonics Ltd (ASX:NAN) share price has fallen 14% in the last few weeks. Is this a buying opportunity for investors?
The post Is the Nanosonics (ASX:NAN) share price in the buy zone? appeared first on Motley Fool Australia. –
The Nanosonics Ltd (ASX: NAN) share price has been out of form in recent weeks.
Since peaking at $6.87 in late August, the infection control specialist’s shares have tumbled 14% lower to $5.89.
Why is the Nanosonics share price down 14% in four weeks?
Investors have been hitting the sell button since the release of its full year results for FY 2020.
However, rather than selling shares because of the pandemic’s impact on its performance, I suspect the real driver of this decline was yet another delay with the company’s plans to launch new products.
Management warned: “Commercialisation of the new technology is no longer expected to be in FY21 but will likely be in FY22, with the ultimate launch timing continuing to be dependent on the necessary technical milestones being met as well as the timing of individual market regulatory approvals.”
This was very disappointing, especially given how many times the company has now failed to deliver on its new product promises.
Is this a buying opportunity?
While Nanosonics certainly isn’t a bargain buy, I still believe it could be a good long term investment.
Though, given the tough trading conditions with COVID-19 and the further delay in its new product launches, I wouldn’t be expecting too much from its shares over the next 12 months.
Sharing a similar view is Goldman Sachs. This morning its analysts put a neutral rating and $5.50 price target on the company’s shares.
It commented: “We believe NAN has successfully transitioned from a disruptive, niche technology provider to a proven leader in its field. However, as a result, there are many facets of execution which this management team must now deliver on to justify the current premium valuation. In particular, we see risk around the timing/impact of new product(s), penetration trajectory, and capital replacement cycle.”
The broker also spoke about its premium valuation and the aforementioned product pipeline.
“The stock trades on 72x NTM EV/EBITDA for 26% growth (vs. sector on 22x for 10%). We like the base business for what it is, and, purely on a DCF basis, we believe it is worth A$2.0/sh. As such, current valuation implies the market is allocating A$4.0/sh, i.e. 66% of total, to future product(s) which were first promised in FY17 but have so far shown negligible progress (the latest expectation is FY22).”
“We note that many ASX HC stocks do not stack up well purely on DCF, but we are not aware of any other example in global healthcare where the market has placed such a high value on a pipeline product with so much uncertainty. That is not to say that we believe it is overvalued, we just don’t have the data to assess either way, and after many delays, we would advocate prudence,” it concluded.
Food for thought.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- Why the Cyclopharma (ASX:CYC) share price surged to record high today
- Rhinomed (ASX:RNO) share price tries following Starpharma’s path to COVID glory
- A practical guide on how to invest in ASX shares
- Broker picks best ASX small cap stocks to buy from the reporting season
- 5 ASX shares I will never sell
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited. The Motley Fool Australia has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Is the Nanosonics (ASX:NAN) share price in the buy zone? appeared first on Motley Fool Australia.
